Skip to main content
letter
. 2011 Jun 7;105(1):89–92. doi: 10.1038/bjc.2011.188

Figure 1.

Figure 1

Kaplan–Meier curves showing the effect of tumour cell content on clinical impact of aberrant (numeric or structural) genetic markers (AGM) in neuroblastoma patients. (A and B) Event-free survival (EFS) and overall survival (OS) of patients with tumours without AGM according to tumour cell content of sample. (C and D) EFS and OS of patients suffering with tumours with AGM according to tumour cell content of sample.